Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)

Last updated: June 28, 2025
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hepatitis B

Treatment

N/A

Clinical Study ID

NCT05621304
10001125
001125-DK
  • Ages 18-100
  • All Genders

Study Summary

Background:

People who were born outside of the country are the largest group of adults infected with chronic hepatitis B virus (HBV) in the US. HBV affects the liver. If not treated, HBV infection can lead to serious liver disease, including cancer. One recent study showed that only 35% of foreign-born US adults were aware of their HBV infections. Foreign-born US adults may also have trouble getting proper care after they are diagnosed with HBV. In one small survey, language, cultural, and financial barriers were cited as the biggest reasons for not receiving care. To help more people with HBV, researchers want to learn how to find and overcome any barriers to care.

Objective:

This natural history study seeks to identify and better understand barriers that prevent foreign-born US adults from getting proper care for HBV infections.

Eligibility:

People aged 18 years and older with chronic HBV who were born outside of the US.

Design:

Participants will visit the NIH clinic 1 time. This visit will take about 20 minutes.

Researchers will review participants medical records and collect information about their HBV.

Participants will complete a survey. They will answer questions about:

Where they came from.

When they came to the US.

How well they have adapted to living in the US.

The health care they have received for HBV.

Their age, gender, and education.

Participants will be paid $10 for completing the survey.

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Male or female, aged >=18 years

  • Diagnosed of chronic HBV (HBsAg-positive)

  • Self-reported country of birth outside of the US

Exclusion

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

-Individuals not able to understand and sign the informed consent document will not be included in the study.

Study Design

Total Participants: 255
Study Start date:
January 03, 2017
Estimated Completion Date:
December 29, 2025

Study Description

Study Description:

This is an observational, prospective study in which Foreign-Born (FB) participants with chronic hepatitis B virus (HBV) will be consented and then surveyed to better understand and identify acculturation-related barriers in the HBV care cascade and to optimize healthcare retention for those with HBV.

Objectives:

Primary Objective:

-To assess the association between recent immigration (defined by less than 10 years length of residence in US) and progression through the HBV care cascade post-diagnosis among foreign-born diagnosed with chronic HBV infection.

Secondary Objectives:

  • To characterize and quantify completion of HBV care metrics after diagnosis (both proportion and time to completion) for a multi-ethnic cohort of foreign-born adults

  • To compare gaps in completion of post-diagnosis care metrics by recent immigrant status and racial/ethnic group

  • To develop and pilot a multi-national survey instrument to accurately and reliably measure immigration-related factors

  • To determine impact of immigration-related factors (e.g. acculturation, language proficiency, region of origin) on completion of care metrics overall and among recent immigrants

Endpoints:

Primary Endpoint:

-The primary endpoint is to assess the proportion of FB diagnosed with HBV who have completed an initial visit for diagnosis of chronic HBV infection (defined as a visit with either primary or specialty provider during which testing for treatment eligibility was ordered).

Secondary Endpoints:

  • Completion of testing to determine eligibility for treatment

    • Minimum sufficient set of labs including hepatitis B e-antigen (HBeAg), ALT, HBV DNA, and HIV testing

    • Fibrosis assessment which can be non-invasive (FIB-4/APRI, US elastography or MR elastography) or invasive (liver biopsy)

  • Treatment uptake if eligible based on AASLD guidelines on treatment eligibility

    • HBV DNA>2000 IU/mL and ALT>2x ULN if HBeAgnegative

    • HBV DNA>20000 IU/mL and ALT>2x ULN if HBeAgpositive

    • Cirrhosis or HCC

    • Family history of HCC

  • Retention in care

    • At least annual visit for HBV diagnosis with appropriate lab tests ordered

    • Ultrasound and AFP for HCC surveillance screening for those who are indicated

Connect with a study center

  • University of Southern California

    Los Angeles, California 90033
    United States

    Active - Recruiting

  • National Institutes of Health Clinical Center

    Bethesda, Maryland 20892
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.